Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M

Ginkgo Bioworks Holdings, Inc.

2022-Q3 EPS reported -$1.19 revenue$379,421,000

Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).
Operating loss $(653)M includes $563M stock-based comp; Adj EBITDA $(70)M vs $(18)M prior year.
Added 15 new Cell Programs (50% growth); cash & equivalents over $1.3B.
Completed Zymergen, Bayer West Sac, Altar, and Circularis acquisitions in October.
FY22 guidance raised: total rev $460-480M (from $425-440M), Biosecurity at least $310M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue Third quarter 2022 Total revenue of $66 million.

Period: third quarter ended September 30, 2022
Revenue: Third quarter 2022 Total revenue of $66 million
Result: reported results

Exact text from the filing

Third quarter 2022 Total revenue of $66 million, down from $78 million in the comparable prior year period, a decrease of 14%

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ginkgo Bioworks Holdings, Inc. reported full year 2022 results: revenue $460 – $480 million. Guidance raised.

Period: full year 2022
Revenue: $460 – $480 million
Guidance: raised
Result: guidance update

Exact text from the filing

Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024981

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.